PDS Biotechnology
PDSB
77 hedge funds and large institutions have $42M invested in PDS Biotechnology in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 15 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
6% more capital invested
Capital invested by funds: $39.7M → $42M (+$2.28M)
1.65% more ownership
Funds ownership: 25.47% → 27.11% (+1.6%)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
1% less funds holding
Funds holding: 78 → 77 (-1)
55% less call options, than puts
Call options by funds: $1.04M | Put options by funds: $2.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
+$1.99M |
| 2 |
Renaissance Technologies
New York
|
+$600K |
| 3 |
Morgan Stanley
New York
|
+$504K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$401K |
| 5 |
BlackRock
New York
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$707K |
| 2 |
LPL Financial
San Diego,
California
|
-$513K |
| 3 |
Two Sigma Investments
New York
|
-$433K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$347K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$131K |
PDSB Hedge Fund Activity: Q4 2023 in Review
77 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2023, worth a combined $42M — up 5.7% from $39.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PDSB and 14 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 26 added.
The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $1.99M. The largest seller was Two Sigma Advisers, cutting an estimated $707K.
- 77 institutional investors held PDS Biotechnology (PDSB) as of Q4 2023, down from 78 in Q3 2023.
- Funds reported $42M of PDS Biotechnology stock for Q4 2023, up 5.7% quarter-over-quarter.
- 14 funds opened new PDS Biotechnology positions in Q4 2023 and 15 closed out, a net change of -1 holder.
- The largest PDS Biotechnology buyer in Q4 2023 was Jefferies Financial Group, an estimated $1.99M added.
- The largest PDS Biotechnology seller in Q4 2023 was Two Sigma Advisers, an estimated $707K sold.
Based on aggregated 13F filings for Q4 2023.